AnteoTech (ADO) H2 2026 earnings summary

Executive summary

• Achieved significant commercial and technical progress in both Advanced Battery Technologies (ABT) and Life Sciences (LS) business units, with a strengthened balance sheet and expanded product portfolio.

• Launched three new ABT products, secured independent validation for Ultranode™ 95, and established new international partnerships in the USA, South Korea, and Japan.

• Life Sciences business expanded in India and Japan, with continued supply to Serum Institute of India and new distributor Cosmo Bio Co., Ltd.

• Completed a $3.8M capital raise and exercised options raising $10M, improving financial stability.

Financial highlights

• Revenue from contracts with customers was $467,589, down from $968,878 in FY2025.

• Total revenue and other income reached $3,129,144, including a $2,588,632 R&D tax concession.

• Net loss after tax was $5,375,654, an improvement from $6,759,135 loss in FY2025.

• Cash on hand at year-end was $5.7M, with an additional $5.5M in term deposits and no debt.

• Total expenses (excluding non-cash items) decreased by 19% year-over-year to $6,857,887.

Outlook and guidance

• Focus on converting customer sample trials and evaluations into sales revenue across both business units and jurisdictions.

• ABT to progress Ultranode™ 95 with US drone battery manufacturers, expand sales of Anteo STM and Anteo C in Asia and the USA, and support Wyon's Ultranode™ 70 development.

• LS to advance CLIA collaboration, secure new product sales, and maintain supply to SII.

• Continued pursuit of strategic partners and investment to accelerate commercialisation.